TSBX (Turnstone Biologics Corp.) Bozor qiymatining balans qiymatiga nisbati

Turnstone Biologics kompaniyasining saraton vaksinalarini ishlab chiqish xarajatlari aksiyadorlik kapitalining sezilarli zaxirasi bilan qoplanadi. Bozor qiymatining buxgalteriya qiymatiga nisbati (market-to-book premium) ushbu barqarorlikni ko'rsatadi va 0.54 ko'rsatkichning joriy darajasini ifodalaydi. Biznesni rivojlantirish AQSh laboratoriyalarida dori formulalarini robotlashtirilgan skrining qilishga va qattiq o'smalar terapiyasi uchun noyob litik viruslarni muhandislik qilishga tayanadi.

turnstonebio.com (TSBX): Kapitallashuvning balans qiymatiga nisbati 21.02.2024dan 24.08.2025gacha

Turnstone Biologics faoliyatining ko'lami bozor qiymatining buxgalteriya qiymatiga nisbati grafigida aks etgan. Ushbu ko'rsatkich spekulyativ qizib ketishni aniqlash uchun emitentning joriy bozor qiymatini uning sof aktivlari bilan solishtiradi. Hisob-kitob barcha aksiyalarning bozor narxini kapital qiymatiga bo'lishga asoslangan. Turnstone Biologics (TSBX) uchun ushbu farq TIDAL-01 sinovlari va TIL ishlab chiqarishni rivojlantirish atrofidagi kutishlar bilan asoslanadi. Investorlar kelajakdagi innovatsiyalar uchun premiumni baholashda ushbu metrikadan foydalanadilar.

Raqobatchilar tahlili

Kapitallashuvning sof aktivlarga nisbati ImmunityBio, Inc.|IMCR (immunocore.com) - Kapitallashuvning balans qiymatiga nisbati|Bozor qiymatining balans qiymatiga nisbati JANX (Janux Therapeutics, Inc.)|Bozor qiymatining balans qiymatiga koeffitsiyenti RCUS|Bozor qiymatining balans qiymatiga nisbati Zymeworks Corp ZYME|Kapitallashuvning balans qiymatiga nisbati Tango Therapeutics Corp (TNGX)|Iovance Biotherapeutics - Bozor kapitallashuvining balans qiymatiga nisbati|immatics.com - Kapitallashuvning sof aktivlarga nisbati|XNCR (Xencor) - Bozor qiymatining balans qiymatiga nisbati|CMPX: Bozor qiymatining balans qiymatiga koeffitsiyenti|Replimune Corp (REPL) - Bozor qiymatining balans qiymatiga nisbati|LYEL (Lyell Pharma) - Bozor qiymatining balans qiymatiga nisbati|Bozor qiymatining balans qiymatiga nisbati IPHA (Innate Pharma S.A.)|Bozor qiymatining balans qiymatiga koeffitsiyenti Pyxis|CGEN: Bozor kapitallashuvining balans qiymatiga nisbati|Bozor qiymatining xususiy kapitalga nisbati IO Biotech Inc IOBT|STRO: Kapitallashuvning sof aktivlarga nisbati|INKT - Bozor qiymatining balans qiymatiga koeffitsiyenti|Kapitallashuvning sof aktivlarga nisbati Werewolf (HOWL)|IMMX - Balans qiymatiga nisbatan bozor qiymati|ALX Oncology - Bozor kapitallashuvining balans qiymatiga nisbati|CUE (Cue Biopharma Inc.) - Balans qiymatiga nisbatan bozor kapitallashuvi|Bozor qiymatining balans qiymatiga nisbati PDSB|Kapitallashuvning sof aktivlarga nisbati SONN|Bozor qiymatining balans qiymatiga nisbati MAIA (MAIA Biotechnology)|Kapitallashuvning sof aktivlarga nisbati liminatuspharma.com LIMN|Kapitallashuvning sof aktivlarga nisbati LVTX (LAVA Therapeutics)|NextCure Inc - Bozor kapitallashuvining balans qiymatiga nisbati|Leap Tx (LPTX) - Bozor qiymatining balans qiymatiga nisbati|INTS: Kapitallashuvning balans qiymatiga nisbati|Bozor qiymatining balans qiymatiga nisbati SNSE|Bozor qiymatining balans qiymatiga koeffitsiyenti therivabio.com|Gritstone bio Inc. - Kapitallashuvning sof aktivlarga nisbati|Bozor qiymatining xususiy kapitalga nisbati Kineta Inc (KA)|Kapitallashuvning sof aktivlarga nisbati NexImmune Corp|Bozor kapitallashuvining balans qiymatiga multiplikatori Vaccinex Inc (VCNX)|Bozor kapitallashuvining balans qiymatiga nisbati Harpoon Therapeutics